# Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

> **NCT05168007** · PHASE3 · UNKNOWN · sponsor: **Whanin Pharmaceutical Company** · enrollment: 342 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** WID-RGC20(Cariprazine) 3mg/day
- **DRUG:** WID-RGC20(Cariprazine) 6mg/day
- **DRUG:** Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day

## Key facts

- **NCT ID:** NCT05168007
- **Lead sponsor:** Whanin Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-19
- **Primary completion:** 2023-07-17
- **Final completion:** 2023-07-31
- **Target enrollment:** 342 (ESTIMATED)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05168007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05168007, "Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05168007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*